EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version 2

Jacques Darcourt, Jan Booij, Klaus Tatsch, Andrea Varrone, Thierry Vander Borght, Özlem L. Kapucu, Kjell Någren, Flavio Nobili, Zuzana Walker, Koen Van Laere

Research output: Contribution to journalReview article

Abstract

These guidelines summarize the current views of the European Association of Nuclear Medicine Neuroimaging Committee (ENC). The aim of the guidelines is to assist nuclear medicine practitioners when making recommendations, performing, interpreting, and reporting the results of clinical dopamine transporter (DAT) single photon emission computed tomography (SPECT) studies using 123I-labelled radiopharmaceuticals. The aim is to achieve a high-quality standard of DAT SPECT imaging, which will increase the diagnostic impact of this technique in neurological practice. The present document is an update of the 2002 guidelines [1] and has been guided by the views of various national societies: the Task Group Neuro-Nuclear-Medicine of the German Society of Nuclear Medicine [2], a consensus statement of the imaging centres included in the "Kompetenznetz-Parkinson" sponsored by the German Federal Ministry of Education, and the Task Group of Neuro-Nuclear-Medicine of the French Society of Nuclear Medicine [3]. The guidelines reflect the individual experience of experts in European countries. The guidelines are intended to present information specifically adapted to European practice. The information provided should be taken in the context of local conditions and regulations.

Original languageEnglish
Pages (from-to)443-450
Number of pages8
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume37
Issue number2
DOIs
Publication statusPublished - Feb 1 2010

Fingerprint

Dopamine Plasma Membrane Transport Proteins
Single-Photon Emission-Computed Tomography
Synaptic Transmission
Guidelines
Ligands
Nuclear Medicine
Brain
Radiopharmaceuticals
Neuroimaging
Education

Keywords

  • Brain
  • DAT
  • Parkinson
  • SPECT

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version 2. / Darcourt, Jacques; Booij, Jan; Tatsch, Klaus; Varrone, Andrea; Vander Borght, Thierry; Kapucu, Özlem L.; Någren, Kjell; Nobili, Flavio; Walker, Zuzana; Van Laere, Koen.

In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 37, No. 2, 01.02.2010, p. 443-450.

Research output: Contribution to journalReview article

Darcourt, J, Booij, J, Tatsch, K, Varrone, A, Vander Borght, T, Kapucu, ÖL, Någren, K, Nobili, F, Walker, Z & Van Laere, K 2010, 'EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version 2', European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 2, pp. 443-450. https://doi.org/10.1007/s00259-009-1267-x
Darcourt, Jacques ; Booij, Jan ; Tatsch, Klaus ; Varrone, Andrea ; Vander Borght, Thierry ; Kapucu, Özlem L. ; Någren, Kjell ; Nobili, Flavio ; Walker, Zuzana ; Van Laere, Koen. / EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version 2. In: European Journal of Nuclear Medicine and Molecular Imaging. 2010 ; Vol. 37, No. 2. pp. 443-450.
@article{3edf05958f684d42a2938d93397e9da3,
title = "EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version 2",
abstract = "These guidelines summarize the current views of the European Association of Nuclear Medicine Neuroimaging Committee (ENC). The aim of the guidelines is to assist nuclear medicine practitioners when making recommendations, performing, interpreting, and reporting the results of clinical dopamine transporter (DAT) single photon emission computed tomography (SPECT) studies using 123I-labelled radiopharmaceuticals. The aim is to achieve a high-quality standard of DAT SPECT imaging, which will increase the diagnostic impact of this technique in neurological practice. The present document is an update of the 2002 guidelines [1] and has been guided by the views of various national societies: the Task Group Neuro-Nuclear-Medicine of the German Society of Nuclear Medicine [2], a consensus statement of the imaging centres included in the {"}Kompetenznetz-Parkinson{"} sponsored by the German Federal Ministry of Education, and the Task Group of Neuro-Nuclear-Medicine of the French Society of Nuclear Medicine [3]. The guidelines reflect the individual experience of experts in European countries. The guidelines are intended to present information specifically adapted to European practice. The information provided should be taken in the context of local conditions and regulations.",
keywords = "Brain, DAT, Parkinson, SPECT",
author = "Jacques Darcourt and Jan Booij and Klaus Tatsch and Andrea Varrone and {Vander Borght}, Thierry and Kapucu, {{\"O}zlem L.} and Kjell N{\aa}gren and Flavio Nobili and Zuzana Walker and {Van Laere}, Koen",
year = "2010",
month = "2",
day = "1",
doi = "10.1007/s00259-009-1267-x",
language = "English",
volume = "37",
pages = "443--450",
journal = "European Journal of Pediatrics",
issn = "0340-6199",
publisher = "Springer Berlin Heidelberg",
number = "2",

}

TY - JOUR

T1 - EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version 2

AU - Darcourt, Jacques

AU - Booij, Jan

AU - Tatsch, Klaus

AU - Varrone, Andrea

AU - Vander Borght, Thierry

AU - Kapucu, Özlem L.

AU - Någren, Kjell

AU - Nobili, Flavio

AU - Walker, Zuzana

AU - Van Laere, Koen

PY - 2010/2/1

Y1 - 2010/2/1

N2 - These guidelines summarize the current views of the European Association of Nuclear Medicine Neuroimaging Committee (ENC). The aim of the guidelines is to assist nuclear medicine practitioners when making recommendations, performing, interpreting, and reporting the results of clinical dopamine transporter (DAT) single photon emission computed tomography (SPECT) studies using 123I-labelled radiopharmaceuticals. The aim is to achieve a high-quality standard of DAT SPECT imaging, which will increase the diagnostic impact of this technique in neurological practice. The present document is an update of the 2002 guidelines [1] and has been guided by the views of various national societies: the Task Group Neuro-Nuclear-Medicine of the German Society of Nuclear Medicine [2], a consensus statement of the imaging centres included in the "Kompetenznetz-Parkinson" sponsored by the German Federal Ministry of Education, and the Task Group of Neuro-Nuclear-Medicine of the French Society of Nuclear Medicine [3]. The guidelines reflect the individual experience of experts in European countries. The guidelines are intended to present information specifically adapted to European practice. The information provided should be taken in the context of local conditions and regulations.

AB - These guidelines summarize the current views of the European Association of Nuclear Medicine Neuroimaging Committee (ENC). The aim of the guidelines is to assist nuclear medicine practitioners when making recommendations, performing, interpreting, and reporting the results of clinical dopamine transporter (DAT) single photon emission computed tomography (SPECT) studies using 123I-labelled radiopharmaceuticals. The aim is to achieve a high-quality standard of DAT SPECT imaging, which will increase the diagnostic impact of this technique in neurological practice. The present document is an update of the 2002 guidelines [1] and has been guided by the views of various national societies: the Task Group Neuro-Nuclear-Medicine of the German Society of Nuclear Medicine [2], a consensus statement of the imaging centres included in the "Kompetenznetz-Parkinson" sponsored by the German Federal Ministry of Education, and the Task Group of Neuro-Nuclear-Medicine of the French Society of Nuclear Medicine [3]. The guidelines reflect the individual experience of experts in European countries. The guidelines are intended to present information specifically adapted to European practice. The information provided should be taken in the context of local conditions and regulations.

KW - Brain

KW - DAT

KW - Parkinson

KW - SPECT

UR - http://www.scopus.com/inward/record.url?scp=77949266557&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949266557&partnerID=8YFLogxK

U2 - 10.1007/s00259-009-1267-x

DO - 10.1007/s00259-009-1267-x

M3 - Review article

C2 - 19838702

AN - SCOPUS:77949266557

VL - 37

SP - 443

EP - 450

JO - European Journal of Pediatrics

JF - European Journal of Pediatrics

SN - 0340-6199

IS - 2

ER -